Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients

Completed · Phase 1

Conditions studied: Non-small Cell Lung Cancer

In brief

This is a multicenter, open-label, phase 1, dose escalation study. The purpose is to determine the highest dose of TG01 that can be safely given to patients with Non-Small Cell Lung Cancer in combination with erlotinib.

Key facts

Study ID

NCT00569114

Run by

Tragara Pharmaceuticals, Inc.

People needed

45

Starts

2007-10-01

Expected to finish

2009-11-01

Last updated by the study team

2010-03-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Comprehensive Blood and Cancer Center — Bakersfield, California, United States
• City of Hope — Duarte, California, United States
• University of Southern California — Los Angeles, California, United States
• University of California at Davis — Sacramento, California, United States
• Nevada Cancer Institute — Las Vegas, Nevada, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.